Albeniz Işil, Demir-Coşkun Ozlem, Türker-Şener Leyla, Baş Aycan, Asoğlu Oktar, Nurten Rüstem
Department of Biophysics, Istanbul University, Istanbul Faculty of Medicine, 34093 Çapa-Istanbul, Turkey.
Oncol Lett. 2011 Jul;2(4):659-664. doi: 10.3892/ol.2011.315. Epub 2011 May 16.
Erythrocyte and lymphocyte NAD(+) glycohydrolase levels were previously found to be elevated in cancer patients. These results were confirmed in an animal model. The administration of live Ehrlich ascites tumor cells to BALB/c mice led to increases in erythrocyte and lymphocyte NAD(+) glycohydrolase, along with tumor development. Serum samples, ascites fluid from mice with developed tumors, serum samples from cancer patients and Ehrlich cell supernatants had a similar stimulatory effect when administered to mice or when incubated with peripheric lymphocytes in culture. These increases were accompanied by the appearance of an anti-CD38 reactive band of 45 kDa in SDS-PAGE/Western blot analyses of erythrocyte ghost and lymphocyte membrane proteins. The results, supported by flow cytometry data, support previous clinical findings that an enhancement in CD38 expression occurs in the hematopoietic system during proliferative processes. Moreover, they suggest that CD38 expression is triggered at least in part by a certain cytokine(s) secreted by cancer cells. Finally, the results emphasize the prospective use of CD38 expression as a marker of tumor development and progression.
先前发现癌症患者的红细胞和淋巴细胞NAD(+)糖水解酶水平升高。这些结果在动物模型中得到了证实。给BALB/c小鼠注射活的艾氏腹水瘤细胞会导致红细胞和淋巴细胞NAD(+)糖水解酶增加，同时肿瘤也会发展。当将来自患有已发展肿瘤的小鼠的腹水、癌症患者的血清样本以及艾氏细胞上清液注射给小鼠或与培养中的外周淋巴细胞一起孵育时，它们具有类似的刺激作用。在对红细胞血影和淋巴细胞膜蛋白进行SDS-PAGE/蛋白质印迹分析时，这些增加伴随着出现一条45 kDa的抗CD38反应带。流式细胞术数据支持的这些结果，证实了先前的临床发现，即在增殖过程中造血系统中CD38表达增强。此外，它们表明CD38表达至少部分是由癌细胞分泌的某种细胞因子触发的。最后，这些结果强调了将CD38表达作为肿瘤发展和进展标志物的潜在用途。
